
Post-transcriptional regulation is the control of gene expression after transcription, involving RNA processing, stability, and translation.Post-transcriptional regulation encompasses all changes and the fate of RNA molecules after transcription (RNA synthesis on a DNA template). These include: splicing (removing non-coding introns and joining exons), alternative splicing (creating different protein variants from one gene), capping, polyadenylation, base editing, transport from the nucleus to the cytoplasm, localization, control of stability and translation rate (protein synthesis). This is critical for dynamic cellular adaptation to environmental conditions and underlies many diseases.
Until the 1970s, regulation of gene expression was largely associated with transcription (the Jacob and Monod operon model). In 1977, Phillip Sharp and Richard Roberts independently discovered introns and splicing in adenoviruses, and in the 1980s, Thomas Cech and Sidney Altman proved the catalytic activity of RNA (ribozymes). In 1993, Victor Ambros and colleagues described the first microRNA, lin-4 in C. elegans, demonstrating the regulatory function of small RNAs. Later, mechanisms of RNA interference (siRNA) and editing (APOBEC enzymes) were discovered. These works shifted the paradigm from linear information transfer DNA→RNA→protein to a complex network of post-transcriptional control, recognized as key in development, immunity, and pathology.
Post-transcriptional mechanisms modulate the fate of the transcript through the formation of ribonucleoprotein complexes. The cap-binding complex attracts elongation factors, the spliceosome recognizes splicing sites by consensus sequences, and the poly(A)-binding protein stabilizes mRNA. MicroRNAs within RISC partially pair with the 3' untranslated region of mRNA and repress translation or cause deadenylation and degradation. Localization is achieved by cytoskeleton-dependent transport and anchoring. Disruptions of these processes underlie many diseases: from spinal muscular atrophy (splicing mutation in SMN1) to cancer (global splicing imbalance).
Explains how cells adapt to stress without changing DNA; underlies RNA vaccines and small interfering RNA therapy.
The same gene can yield over 38,000 protein variants through alternative splicing—like assembling different sentences from the same set of words.















